Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 86.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 65,014 shares of the company’s stock after purchasing an additional 30,167 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Eton Pharmaceuticals were worth $390,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Thompson Siegel & Walmsley LLC acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $420,000. Aristides Capital LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at $658,000. Renaissance Technologies LLC raised its position in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the period. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth about $3,095,000. Finally, Stonepine Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth about $362,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Trading Up 6.2 %

NASDAQ ETON opened at $13.53 on Friday. Eton Pharmaceuticals, Inc. has a 1-year low of $3.03 and a 1-year high of $13.72. The firm’s fifty day simple moving average is $8.67 and its 200-day simple moving average is $5.54. The company has a market capitalization of $349.56 million, a PE ratio of -61.50 and a beta of 1.25.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Craig Hallum lifted their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up from $11.00) on shares of Eton Pharmaceuticals in a research report on Tuesday, November 26th.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average price of $4.65 per share, with a total value of $267,375.00. Following the completion of the transaction, the insider now owns 2,660,000 shares in the company, valued at $12,369,000. The trade was a 2.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have bought 85,600 shares of company stock worth $462,674 over the last 90 days. 14.89% of the stock is currently owned by corporate insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.